Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD-Reference-Cited by-同舟云学术

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD

Published:2015-07-02 Issue:1 Volume:13 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Puhan Milo A.,Yu Tsung,Boyd Cynthia M.,ter Riet Gerben

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1186/s12916-015-0398-0/fulltext.html

Reference42 articles.

1. European Medicines Agency – Human Medicines: European Public Assessment Report for Daliresp. 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002398/human_med_001415.jsp&murl=menus/medi . Accessed 6 April 2015.

2. US Department of Health and Human Services. Food and Drug Administration. Approval package for: application number: 022522Orig1s000. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000Approv.pdf . Accessed 6 April 2015.

3. Chong J, Poole P, Leung B, Pn B. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309.

4. Lone N, Oba Y. Roflumilast: a green signal is yet to come. J Thorac Dis. 2013;5:213–5.

5. Global Initiative for Chronic Obstructive Lung Disease. Updated 2014. Chapter 3: Therapeutic options, p. 25. http://www.goldcopd.org/Guidelines/guidelines-resources.html . Accessed 6 April 2015.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A proposal for using benefit-risk methods to improve the prominence of adverse event results when reporting trials;Trials;2024-06-22

2. A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force;Value in Health;2023-02

3. Long-term treatment with roflumilast improves learning of fear extinction memory and anxiety-like response in a type-1 diabetes mellitus animal model;Behavioural Brain Research;2023-02

4. Building Infrastructure to Exploit Evidence from Patient Preference Information (PPI) Studies: A Conceptual Blueprint;Applied Sciences;2022-07-20

5. Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance;Clinical Trials;2022-02-13